secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001127537-26-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q4 revenue declines 5% YoY; full year up 8%; guides flat FY2026 revenue $90-92M
--------------------------------------------------------------------------------

- Q4 2025 revenue $22.6M, down 5% YoY (down 7% constant currency); US revenue fell 11% to $14.1M.
- Full year 2025 revenue $90.5M, up 8% YoY (7% constant currency); international revenue up 23% to $33.5M.
- Net loss improved: Q4 net loss $10.4M ($0.25/sh) vs $13.2M ($0.33/sh); full year loss $54.0M vs $56.4M.
- Secured up to $60M in new 5-year interest-only credit facility extending debt maturity to 2031; cash $69.8M at year end.
- FY2026 guidance: revenue $90-92M (roughly flat); gross margin ~75%; operating expenses $113-115M; cash burn ~$23M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753726000003/0001127537-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753726000003/lung-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001127537-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer